Advertisement

Search Results

Advertisement



Your search for Hope matches 3185 pages

Showing 1 - 50


lung cancer

Defying the Odds

In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...

Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician

Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...

breast cancer

New Guideline Reflects the Latest Evidence in Support of Postmastectomy Radiation Therapy for Patients With Breast Cancer

A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...

neuroendocrine tumors

Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma/Paraganglioma

Belzutifan induced durable responses without surgery in patients with advanced pheochromocytoma or paraganglioma and demonstrated manageable safety in the phase II LITESPARK-015 trial, according to findings presented during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract...

lung cancer
issues in oncology

Multidisciplinary Program Doubles Lung Cancer Screening Rates

Researchers have created a roadmap to improve national lung cancer screening rates that doubled lung cancer screening rates through their multidisciplinary lung cancer screening program, according to a study published in NEJM Catalyst. “Our biggest success was not only screening a high percentage...

lymphoma
skin cancer

Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial

In a randomized phase II trial, Christiane Querfeld, MD, PhD, and colleagues investigated the effects of a PD-L1–blocking strategy for targeting both the innate and adaptive immune systems in cutaneous T-cell lymphoma (CTCL). At the 2025 Society of Hematologic Oncology (SOHO) Annual Meeting,1 Dr....

issues in oncology

Considerations on Cancer Drug Development

In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....

issues in oncology

Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers

Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatments, including biologics or radiation therapy. An analysis by Joseph M. Unger, PhD, MS, Professor,...

breast cancer
ai in oncology

$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening

The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...

gynecologic cancers

HPV Self-Sampling Collection Test Improved Cervical Cancer Screening Rates Among Asian American Women

Studies have shown that human papillomavirus (HPV) infection—especially with high-risk variants such as HPV16 and HPV18—is the primary cause of cervical cancer, accounting for about 95% of all cases. Although cervical cancer screening through Pap smear tests can detect the presence of precancerous...

lung cancer

City of Hope Awarded $23.7 Million to Map Biomarkers in NSCLC

City of Hope® has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will help City of Hope to create a biomap of tumor changes that cause immunotherapy resistance in advanced ...

geriatric oncology

ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings

On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...

geriatric oncology

Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer

Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medications that are associated with increased frailty at the time of their cancer diagnosis, according...

issues in oncology

How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer

Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...

hematologic malignancies

Is Cure Finally Achievable in Multiple Myeloma?

After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...

breast cancer

New Report on Breast Reconstruction Preferences Among African American Women

For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery....

Understanding Accelerated Aging in Survivors of Childhood Cancers

Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...

gastrointestinal cancer

Gastrointestinal Tumor Microbes May Predict Prognosis and Therapeutic Response

Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment, and those roles make them appealing targets for new therapies. Tumor microbiota–based tools could also help identify high-risk patients and those most susceptible to metastases, and possibly be...

ai in oncology

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...

hepatobiliary cancer

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...

breast cancer
cardio-oncology

Case 3: Cardiac Risk Stratification

This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...

breast cancer
cardio-oncology

Case 2: CDK4/6 Inhibitor Choice in Medically Fragile Patients With Heart Failure

This is Part 2 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss managing...

breast cancer
cardio-oncology

Case 1: Management of Cardiovascular Risk Factors

This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...

breast cancer
symptom management

Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?

Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...

issues in oncology

Can a Mitochondrial Antioxidant Drive Metastasis?

Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...

lung cancer

A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger

The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...

survivorship

Childhood Cancer Survivors and Long-Term Risks for Health Conditions: New Data

Some survivors of childhood cancers face a continued elevated risk of premature mortality, new cancers, chronic conditions, and other adverse health conditions as they grow older, according to new findings published in the Journal of Clinical Oncology.  An increased risk for cancer and other...

kidney cancer
genomics/genetics

Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers

Results from a recent study may help to explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for patients with advanced kidney cancers. The collaborative work ...

genomics/genetics
ai in oncology

LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility

Large language models (LLMs) can be trained to understand how each patient’s somatic mutations impact their cancer prognosis and possible response to therapy, according to a presentation at the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning. John-William...

hepatobiliary cancer

STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA

A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...

hematologic malignancies
health-care policy

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list price. This new price will go into effect in January 2026. Negotiations began following passage...

pancreatic cancer

Surviving Pancreatic Cancer

I’ve been blessed to have remained healthy for most of my life. In fact, I can’t remember ever spending a night in the hospital until I was diagnosed with pancreatic cancer, at age 86, in the summer of 2024. And even then, the symptoms that drove me to seek care in the emergency room of my local...

hematologic malignancies

Updates in Systemic Light-Chain Amyloidosis

Systemic amyloid light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chains, produced by clonal CD38-positive plasma cells, as insoluble amyloid fibrils in vital organs. It is a disease that can progress rapidly and is fatal without treatment. The past decade...

thyroid cancer
neuroendocrine tumors
ai in oncology

Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers

Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Reports of the development and validation of the models were presented at ENDO...

skin cancer

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...

hepatobiliary cancer

Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial

In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...

skin cancer

RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma

When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...

lung cancer
immunotherapy

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...

leukemia

Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies

Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...

solid tumors
hematologic malignancies

Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells

Many cytotoxic chemotherapy agents have long-term biological consequences, including premature aging of the cell population structure of healthy blood, the results of a study of the genetic effects of chemotherapy showed. These findings published in Nature Genetics may help to guide future...

breast cancer

Can Hormone Therapy Affect Breast Cancer Risk in Younger Women?

Investigators have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use this type of hormone therapy. Additionally, women...

colorectal cancer
immunotherapy

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology. Background Colorectal cancer is the second-leading cause of...

hematologic malignancies

Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...

breast cancer

Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader...

lymphoma

New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma

The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...

breast cancer
issues in oncology
cardio-oncology

Gut Microbiome May Hold Key to Avoiding Chemotherapy-Related Cardiotoxicity in Patients With Breast Cancer

A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to new findings presented by Antoniades et al at the European Society of Cardiology (ESC) Cardio-Oncology 2025 annual conference. Background Cardiotoxicity is a...

breast cancer
genomics/genetics

How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival

A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....

gastrointestinal cancer

Outcomes of Oncologic Extended Resection for Gallbladder Cancer: Results of a Global Analysis

In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...

solid tumors
supportive care
symptom management

Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder

A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...

geriatric oncology
supportive care
global cancer care

Could A Telehealth Program Enhance Geriatric Cancer Care?

A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...

Advertisement

Advertisement




Advertisement